154 related articles for article (PubMed ID: 35078739)
1. Effect of Prior Therapy and Disease Refractoriness on the Efficacy and Safety of Oral Selinexor in Patients with Diffuse Large B-cell Lymphoma (DLBCL): A Post-hoc Analysis of the SADAL Study.
Schuster M; Zijlstra J; Casasnovas RO; Vermaat JSP; Kalakonda N; Goy A; Choquet S; Neste EVD; Hill B; Thieblemont C; Cavallo F; De la Cruz F; Kuruvilla J; Hamad N; Jaeger U; Caimi P; Gurion R; Warzocha K; Bakhshi S; Sancho JM; Follows G; Egyed M; Offner F; Vassilakopoulos T; Samal P; Ku M; Ma X; Corona K; Chamoun K; Shah J; Shacham S; Kauffman MG; Canales M; Maerevoet M
Clin Lymphoma Myeloma Leuk; 2022 Jul; 22(7):483-494. PubMed ID: 35078739
[TBL] [Abstract][Full Text] [Related]
2. Selinexor in patients with relapsed or refractory diffuse large B-cell lymphoma (SADAL): a single-arm, multinational, multicentre, open-label, phase 2 trial.
Kalakonda N; Maerevoet M; Cavallo F; Follows G; Goy A; Vermaat JSP; Casasnovas O; Hamad N; Zijlstra JM; Bakhshi S; Bouabdallah R; Choquet S; Gurion R; Hill B; Jaeger U; Sancho JM; Schuster M; Thieblemont C; De la Cruz F; Egyed M; Mishra S; Offner F; Vassilakopoulos TP; Warzocha K; McCarthy D; Ma X; Corona K; Saint-Martin JR; Chang H; Landesman Y; Joshi A; Wang H; Shah J; Shacham S; Kauffman M; Van Den Neste E; Canales MA
Lancet Haematol; 2020 Jul; 7(7):e511-e522. PubMed ID: 32589977
[TBL] [Abstract][Full Text] [Related]
3. Survival among patients with relapsed/refractory diffuse large B cell lymphoma treated with single-agent selinexor in the SADAL study.
Maerevoet M; Zijlstra JM; Follows G; Casasnovas RO; Vermaat JSP; Kalakonda N; Goy A; Choquet S; Van Den Neste E; Hill B; Thieblemont C; Cavallo F; De la Cruz F; Kuruvilla J; Hamad N; Jaeger U; Caimi P; Gurion R; Warzocha K; Bakhshi S; Sancho JM; Schuster M; Egyed M; Offner F; Vassilakopoulos TP; Samal P; Ku M; Ma X; Corona K; Chamoun K; Shah J; Shacham S; Kauffman MG; Canales M
J Hematol Oncol; 2021 Jul; 14(1):111. PubMed ID: 34271963
[TBL] [Abstract][Full Text] [Related]
4. Comparison of the Effectiveness and Safety of the Oral Selective Inhibitor of Nuclear Export, Selinexor, in Diffuse Large B Cell Lymphoma Subtypes.
Casasnovas RO; Follows G; Zijlstra JM; Vermaat JSP; Kalakonda N; Choquet S; Neste EVD; Hill B; Thieblemont C; Cavallo F; la Cruz F; Kuruvilla J; Hamad N; Jaeger U; Caimi PF; Gurion R; Warzocha K; Bakhshi S; Sancho JM; Schuster M; Egyed M; Offner F; Vassilakopoulos TP; Samal P; Ku M; Ma X; Chamoun K; Shah J; Canales M; Maerevoet M; Shacham S; Kauffman MG; Goy A
Clin Lymphoma Myeloma Leuk; 2022 Jan; 22(1):24-33. PubMed ID: 34493477
[TBL] [Abstract][Full Text] [Related]
5. A drug profile on selinexor for the treatment of refractory diffuse large B-cell lymphoma.
Sylvain C
Expert Rev Hematol; 2022 Mar; 15(3):195-201. PubMed ID: 35318887
[TBL] [Abstract][Full Text] [Related]
6. FDA Approval Summary: Selinexor for Relapsed or Refractory Diffuse Large B-Cell Lymphoma.
Kasamon YL; Price LSL; Okusanya OO; Richardson NC; Li RJ; Ma L; Wu YT; Theoret M; Pazdur R; Gormley NJ
Oncologist; 2021 Oct; 26(10):879-886. PubMed ID: 34132444
[TBL] [Abstract][Full Text] [Related]
7. The Association between Patient Characteristics and the Efficacy and Safety of Selinexor in Diffuse Large B-Cell Lymphoma in the SADAL Study.
Zijlstra JM; Follows G; Casasnovas RO; Vermaat JSP; Kalakonda N; Choquet S; Hill B; Thieblemont C; Cavallo F; Cruz F; Kuruvilla J; Hamad N; Jaeger U; Caimi P; Gurion R; Warzocha K; Bakhshi S; Sancho JM; Schuster M; Egyed M; Offner F; Vassilakopoulos TP; Samal P; Ku M; Xu J; Corona K; Chamoun K; Shah J; Canales M; Maerevoet M
Cancers (Basel); 2022 Feb; 14(3):. PubMed ID: 35159058
[TBL] [Abstract][Full Text] [Related]
8. Selinexor (KTP-330) - a selective inhibitor of nuclear export (SINE): anti-tumor activity in diffuse large B-cell lymphoma (DLBCL).
Ben-Barouch S; Kuruvilla J
Expert Opin Investig Drugs; 2020 Jan; 29(1):15-21. PubMed ID: 31847605
[No Abstract] [Full Text] [Related]
9. XPO1 expression worsens the prognosis of unfavorable DLBCL that can be effectively targeted by selinexor in the absence of mutant p53.
Deng M; Zhang M; Xu-Monette ZY; Pham LV; Tzankov A; Visco C; Fang X; Bhagat G; Zhu F; Dybkaer K; Chiu A; Tam W; Zu Y; Hsi ED; Choi WWL; Huh J; Ponzoni M; Ferreri AJM; Møller MB; Parsons BM; van Krieken JH; Piris MA; Winter JN; Hagemeister F; Alinari L; Li Y; Andreeff M; Xu B; Young KH
J Hematol Oncol; 2020 Nov; 13(1):148. PubMed ID: 33148342
[TBL] [Abstract][Full Text] [Related]
10. Health-related quality of life and utility outcomes with selinexor in relapsed/refractory diffuse large B-cell lymphoma.
Shah J; Shacham S; Kauffman M; Daniele P; Tomaras D; Tremblay G; Casasnovas RO; Maerevoet M; Zijlstra J; Follows G; P Vermaat JS; Kalakonda N; Goy AH; Choquet S; Den Neste EV; Hill BT; Thieblemont C; Cavallo F; la Cruz F; Kuruvilla J; Hamad N; Bouabdallah R; Jäger U; Caimi P; Gurion R; Warzocha K; Bakhshi S; Sancho JM; Schuster M; Egyed M; Offner F; Vasilakopoulos TP; Samal P; Nagy A; Ku M; Canales Albendea MÁ
Future Oncol; 2021 Apr; 17(11):1295-1310. PubMed ID: 33528286
[TBL] [Abstract][Full Text] [Related]
11. Selinexor population pharmacokinetic and exposure-response analyses to support dose optimization in patients with diffuse large B-cell lymphoma.
Xu H; Li H; Wada R; Bader JC; Tang S; Shah J; Shacham S
Cancer Chemother Pharmacol; 2021 Jul; 88(1):69-79. PubMed ID: 33770229
[TBL] [Abstract][Full Text] [Related]
12. Selinexor Combined with Ibrutinib Demonstrates Tolerability and Safety in Advanced B-Cell Malignancies: A Phase I Study.
Stephens DM; Huang Y; Ruppert AS; Walker JS; Canfield D; Cempre CB; Fu Q; Baker S; Hu B; Shah H; Vadeboncoeur R; Rogers KA; Bhat S; Jaglowski SM; Lockman H; Lapalombella R; Byrd JC; Woyach JA
Clin Cancer Res; 2022 Aug; 28(15):3242-3247. PubMed ID: 35608822
[TBL] [Abstract][Full Text] [Related]
13. Selective inhibition of nuclear export with selinexor in patients with non-Hodgkin lymphoma.
Kuruvilla J; Savona M; Baz R; Mau-Sorensen PM; Gabrail N; Garzon R; Stone R; Wang M; Savoie L; Martin P; Flinn I; Jacoby M; Unger TJ; Saint-Martin JR; Rashal T; Friedlander S; Carlson R; Kauffman M; Shacham S; Gutierrez M
Blood; 2017 Jun; 129(24):3175-3183. PubMed ID: 28468797
[TBL] [Abstract][Full Text] [Related]
14. Safety, tolerability, and preliminary activity of CUDC-907, a first-in-class, oral, dual inhibitor of HDAC and PI3K, in patients with relapsed or refractory lymphoma or multiple myeloma: an open-label, dose-escalation, phase 1 trial.
Younes A; Berdeja JG; Patel MR; Flinn I; Gerecitano JF; Neelapu SS; Kelly KR; Copeland AR; Akins A; Clancy MS; Gong L; Wang J; Ma A; Viner JL; Oki Y
Lancet Oncol; 2016 May; 17(5):622-31. PubMed ID: 27049457
[TBL] [Abstract][Full Text] [Related]
15. Selinexor therapy for multiple myeloma and non-Hodgkin lymphomas.
Goldsmith SR; Liu L; Shiah K
Curr Opin Oncol; 2022 Sep; 34(5):524-530. PubMed ID: 35880450
[TBL] [Abstract][Full Text] [Related]
16. A Phase II Study of the Efficacy and Safety of Oral Selinexor in Recurrent Glioblastoma.
Lassman AB; Wen PY; van den Bent MJ; Plotkin SR; Walenkamp AME; Green AL; Li K; Walker CJ; Chang H; Tamir S; Henegar L; Shen Y; Alvarez MJ; Califano A; Landesman Y; Kauffman MG; Shacham S; Mau-Sørensen M
Clin Cancer Res; 2022 Feb; 28(3):452-460. PubMed ID: 34728525
[TBL] [Abstract][Full Text] [Related]
17. Selective Inhibition of Nuclear Export With Oral Selinexor for Treatment of Relapsed or Refractory Multiple Myeloma.
Vogl DT; Dingli D; Cornell RF; Huff CA; Jagannath S; Bhutani D; Zonder J; Baz R; Nooka A; Richter J; Cole C; Vij R; Jakubowiak A; Abonour R; Schiller G; Parker TL; Costa LJ; Kaminetzky D; Hoffman JE; Yee AJ; Chari A; Siegel D; Fonseca R; Van Wier S; Ahmann G; Lopez I; Kauffman M; Shacham S; Saint-Martin JR; Picklesimer CD; Choe-Juliak C; Stewart AK
J Clin Oncol; 2018 Mar; 36(9):859-866. PubMed ID: 29381435
[TBL] [Abstract][Full Text] [Related]
18. Novel Therapies for Relapsed or Refractory Diffuse Large B-Cell Lymphoma.
Harris LJ; Patel K; Martin M
Int J Mol Sci; 2020 Nov; 21(22):. PubMed ID: 33202794
[TBL] [Abstract][Full Text] [Related]
19. Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia.
Plosker GL; Figgitt DP
Drugs; 2003; 63(8):803-43. PubMed ID: 12662126
[TBL] [Abstract][Full Text] [Related]
20. Phase 2 study of the Exportin 1 inhibitor selinexor in patients with recurrent gynecological malignancies.
Vergote IB; Lund B; Peen U; Umajuridze Z; Mau-Sorensen M; Kranich A; Van Nieuwenhuysen E; Haslund C; Nottrup T; Han SN; Concin N; Unger TJ; Chai Y; Au N; Rashal T; Joshi A; Crochiere M; Landesman Y; Shah J; Shacham S; Kauffman M; Mirza MR
Gynecol Oncol; 2020 Feb; 156(2):308-314. PubMed ID: 31822399
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]